Licarin A

1. Matsui T, Ito C, Masubuchi S, Itoigawa M. Licarin A is a candidate compound for the treatment of immediate hypersensitivity via inhibition of rat mast cell line RBL-2H3 cells. J Pharm Pharmacol. 2015 Dec;67(12):1723-32. doi: 10.1111/jphp.12475. Epub 2015 Sep 17. PubMed PMID: 26376734. 2. N?ris PL, Caldas JP, Rodrigues YK, Amorim FM, Leite JA, Rodrigues-Mascarenhas S, Barbosa-Filho JM, Rodrigues LC, Oliveira MR. Neolignan Licarin A presents effect against Leishmania (Leishmania) major associated with immunomodulation in vitro. Exp Parasitol. 2013 Oct;135(2):307-13. doi: 10.1016/j.exppara.2013.07.007. Epub 2013 Jul 24. PubMed PMID: 23891943. 3. Le?n-D?az R, Meckes-Fischer M, Valdovinos-Mart?nez L, Campos MG, Hern?ndez-Pando R, Jim?nez-Arellanes MA. Antitubercular activity and the subacute toxicity of (-)-Licarin A in BALB/c mice: a neolignan isolated from Aristolochia taliscana. Arch Med Res. 2013 Feb;44(2):99-104. doi: 10.1016/j.arcmed.2012.12.006. Epub 2013 Jan 4. PubMed PMID: 23291382. 4. Pereira AC, Magalh?es LG, Janu?rio AH, Pauletti PM, Cunha WR, Bastos JK, Nanayakkara DN, Silva ML. Enantiomeric resolution of (?)-licarin A by high-performance liquid-chromatography using a chiral stationary phase. J Chromatogr A. 2011 Sep 28;1218(39):7051-4. doi: 10.1016/j.chroma.2011.07.093. Epub 2011 Aug 6. PubMed PMID: 21868019.